| Selective sodium-glucose cotransporter-2 inhibitors in the improvement of hemoglobin and hematocrit in patients with type 2 diabetes mellitus: A network meta-analysis. | 2024 | Frontiers in Endocrinology |
| Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients. | 2024 | European Journal of Clinical Pharmacology |
| The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis. | 2023 | Frontiers in Psychcology |
| Effect of sodium–glucose cotransporter 2 inhibitors on insulin resistance; a systematic review and meta-analysis. | 2023 | Acta Diabetologica |
| The efficacy of sodium-glucose cotransporter-2 inhibitors in improving morbidity and mortality of heart failure: A systematic review. | 2023 | Cureus |
| The effects of cardioprotective antidiabetic therapy on microbiota in patients with type 2 diabetes mellitus-a systematic review. | 2023 | Internal Journal of Molecular Sciences |
| Systematic review of sodium-glucose cotransporter 2 inhibitors: A hopeful prospect in tackling heart failure-related events. | 2023 | European Journal of Heart Failure |
| Serum uric acid lowering and effects of sodium-glucose cotransporter-2 inhibitors on gout: A meta-analysis and meta-regression of randomized controlled trials. | 2023 | Diabetes, Obesity and Metabolism |
| Effects of empagliflozin on serum uric acid level of patients with type 2 diabetes mellitus: A systematic review and meta-analysis. | 2023 | Diabetology & Metabolic Syndrome |
| Impact of SGLT2 inhibitors on patient outcomes: A network meta-analysis. | 2023 | Cardiovascular Diabetology |
| Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: A systematic review and network meta-analysis of randomized controlled trials. | 2023 | Frontiers in Endocrinology |
| Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. | 2023 | Frontiers in Endocrinology |
| Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis of randomized clinical trials. | 2023 | Frontiers in Endocrinology |
| Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: A meta-analysis of randomized controlled trials. | 2023 | Heart Failure Reviews |
| Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: A systematic review and meta-analysis of randomized controlled trials. | 2023 | Frontiers in Cardiovascular Medicine |
| Cardiovascular benefits and safety of sotagliflozin in type 2 diabetes mellitus patients with heart failure or cardiovascular risk factors: A Bayesian network meta-analysis. | 2023 | Frontiers in Pharmacology |
| Impacts of sodium/glucose cotransporter-2 inhibitors on circulating uric acid concentrations: A systematic review and meta-analysis. | 2022 | Journal of Diabetes Research |
| Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: A systematic review and meta-analysis. | 2022 | Canadian Journal of Diabetes |
| Comparative cardiovascular outcomes of SGLT2 inhibitors in type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials. | 2022 | Frontiers in Endocrinology |
| Comparative efficacy of five SGLT2i on cardiorenal events: A network meta-analysis based on ten CVOTS. | 2022 | American Journal of Cardiovascular Drugs |
| Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: A systemic review and meta-analysis of randomized controlled trials. | 2022 | Journal of Cardiovascular Pharmacology |
| Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: A systematic review and meta-analysis of randomized trials. | 2022 | European Heart Journal- Quality of Care and Clinical Outcomes |
| Beneficial effect of sodium-glucose co-transporter 2 inhibitors on left ventricular function | 2022 | The Journal of Clinical Endocrinology & Metabolism |
| Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: A systematic review and meta-analysis. | 2022 | European Journal of Preventative Cardiology |
| Relationship between SGLT-2i and ocular diseases in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. | 2022 | Frontiers in Endocrinology |
| Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: A network meta-analysis based on randomized controlled trials. | 2022 | Journal of Clinical Pharmacy and Therapeutics |
| The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis. | 2021 | Diabetes, Obesity and Metabolism |
| Do SGLT2 inhibitors improve cardio-renal outcomes in patients with type II diabetes mellitus: A systematic review. | 2021 | Cureus |
| Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials. | 2021 | Heart Rhythm |
| Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients. | 2021 | Medicine |
| Microvascular benefits of new antidiabetic agents: A systematic review and network meta-analysis of kidney outcomes. | 2021 | Journal of Clinical Endocrinology & Metabolism |
| Empagliflozin in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials. | 2021 | Frontiers in Cardiovascular Medicine |
| Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. | 2021 | Diabetes Research and Clinical Practice |
| Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: A systematic review and network meta-analysis. | 2021 | Cardiovascular Drugs and Therapy |
| Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. | 2021 | Diabetes, Obesity and Metabolism |
| Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials. | 2021 | Heart Failure Reviews |
| High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials. | 2021 | Diabetes, Obesity and Metabolism |
| Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis. | 2020 | IJC Heart and Vasculature |
| Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: A systematic review and network meta-analysis. | 2020 | Annals of Internal Medicine |
| SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials | 2020 | The Lancet Diabetes and Endocrinology |
| Association of glucose-lowering medications with cardiovascular outcomes: An umbrella review and evidence map. | 2020 | The Lancet Diabetes and Endocrinology |
| Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis | 2020 | PLoS One |
| Efficacy and safety of SGLT-2 inhibitors for treatment of diabetes mellitus among kidney transplant patients: A systematic review and meta-analysis. | 2020 | Medical sciences |
| Effect of sodium-dependent glucose transporter inhibitors on glycated hemoglobin A1c after 24 weeks in patients with diabetes mellitus: A systematic review and meta-analysis. | 2020 | Medicine |
| Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis. | 2019 | PLoS Medicine |
| Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials. | 2019 | Diabetes Research and Clinical Practice |
